mSEPT9检测在结直肠癌诊断和复发监测中的价值  

The value of mSEPT9 detection in the diagnosis and recurrence monitoring of colorectal cancer

作　　者：陈娇娇 李蓉[1] 张可 胡凤娣[1] 谢琳[1] CHEN Jiaojiao;LI Rong;ZHANG Ke;HU Fengdi;XIE Lin(Department of Gastrointestinal Oncology,the Third Affiliated Hospital of Kunming Medical University,Tumor Hospital of Yunnan Province,Yunnan Kunming 650118,China.)

机构地区：[1]昆明医科大学第三附属医院(云南省肿瘤医院)消化肿瘤内科,云南昆明650118

出　　处：《现代肿瘤医学》2024年第15期2783-2788,共6页Journal of Modern Oncology

基　　金：云南省科技厅基础研究计划(编号:202101AY070001-177)。

摘　　要：目的:探讨Septin9基因甲基化(Septin9 gene methylation, mSEPT9)检测在结直肠癌(colorectal cancer, CRC)诊断和复发监测中的价值。方法:回顾性分析2018年01月至2021年12月在该院确诊并行根治性手术的CRC患者130例,再选择同时间段非CRC患者132例作为对照组,其中腺瘤组72例,健康对照组60例。探究血浆mSEPT9检测在CRC诊断中的作用,并分析mSEPT9在CRC患者术后复发监测中的意义。结果:健康对照组和腺瘤组患者血浆mSEPT9、血清CEA检测的阳性率均低于CRC组,差异均有统计学意义(P<0.05);健康对照组和腺瘤组各指标检测阳性率间比较,差异无统计学意义(P>0.05)。将CRC发生的危险因素单独列出并以评分的形式量化,生成了预测CRC发生概率的列线图。对CRC患者进行术后随访,多因素Logistic回归分析结果显示:TNM分期(Ⅲ、Ⅳ)期、术前mSEPT9阳性是CRC患者术后复发的独立危险因素(P<0.05)。结论:mSEPT9可作为诊断CRC和监测术后复发的分子标志物。Objective:To investigate the value of Septin9 gene methylation(mSEPT9)in the diagnosis and recurrence monitoring of colorectal cancer(CRC).Methods:From January 2018 to December 2021,130 patients with CRC who were diagnosed and underwent radical surgery in the hospital were retrospectively analyzed,and 132 patients without CRC at the same time were selected as the control group.There were 72 cases in adenoma group and 60 cases in healthy control group.To explore the role of plasma mSEPT9 detection in the diagnosis of CRC,and to analyze the significance of mSEPT9 in the monitoring of postoperative recurrence in CRC patients.Results:The positive rates of plasma mSEPT9 and serum CEA in healthy control group and adenoma group were lower than those in colorectal cancer group,and the differences were statistically significant(P<0.05).The risk factors of CRC were listed separately and quantified in the form of scores,and a nomogram for predicting the probability of CRC was generated.Multivariate Logistic regression analysis showed that TNM stage(Ⅲ,Ⅳ)and preoperative mSEPT9 positive were independent risk factors for postoperative recurrence of CRC patients(P<0.05).Conclusion:Plasma mSEPT9 can be used as a molecular marker for the diagnosis of CRC and monitoring postoperative recurrence.

关 键 词：结直肠癌 mSEPT9 诊断 复发 

分 类 号：R735.3[医药卫生—肿瘤]